Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine gel for prevention of erythema and post-inflammatory hyperpigmentation after ablative CO2 laser
IRCT20150825023753N29Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of brimonidine in Post-inflammatory hyperpigmentation (PIH) and erythema (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Rate of post-inflammatory hyperpigmentation. Started Apr 2025; status: completed.
02
Drugs
brimonidine
03
Conditions
Post-inflammatory hyperpigmentation (PIH)erythema
Beyond the preview
Go deeper on IRCT20150825023753N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150825023753N29.